+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Molecular markers for prostate cancer

Molecular markers for prostate cancer

Cancer Letters 249(1): 5-13

Serum PSA testing has been used for over 20 years as an aid in the diagnosis and management of prostate cancer. Although highly sensitive, it suffers from a lack of specificity, showing elevated serum levels in a variety of other conditions including prostatitis, benign prostate hyperplasia, and non-cancerous neoplasia. During this period, numerous serum protein analytes have been investigated as alternative and/or supplemental tests for PSA, however in general these analytes have likewise suffered from a lack of specificity, often showing serum elevations in other clinical presentations. More recently, molecular assays targeting prostate disease at the DNA or RNA level have been investigated for potential diagnostic and prognostic utility. With the aid of modern genomics technologies, a variety of molecular biomarkers have been discovered that show potential for specific correlation with prostate cancer. Much of this discovery has been retrospective, using microdissected tissue from prostatectomy. The goal of current research is to apply genomic assays to noninvasive specimens such as blood and urine. Progress in this area is the subject of this review.

(PDF emailed within 0-6 h: $19.90)

Accession: 013763144

Download citation: RISBibTeXText

PMID: 17303324

DOI: 10.1016/j.canlet.2006.12.029

Related references

Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer. American Journal of Pathology 150(5): 1511-1521, 1997

Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology 59(1): 2-8, 2002

Molecular and prognostic markers in prostate cancer. A study of cell-cycle regulators, angiogenesis and candidate markers. Apmis. Supplementum 2008(123): 5-62, 2008

Molecular and prognostic markers in prostate cancer - A study of cell-cycle regulators, angiogenesis and candidate markers - Introduction. 2007

Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. American Journal of Human Genetics 62(3): 653-658, 1998

Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer. Canadian Journal of Urology 13 Suppl 2: 2-10, 2006

Molecular markers of prostate cancer. Urologic Oncology 24(6): 538-551, 2006

Haemostatic molecular markers in patients undergoing radical retropubic prostatectomy for prostate cancer and submitted to prophylaxis with unfractioned or low molecular weight heparin. Minerva Anestesiologica 67(10): 693-703, 2001

Molecular markers in the diagnosis of prostate cancer. Critical Reviews in Oncology/Hematology 61(2): 104-139, 2006

Molecular markers and mortality in prostate cancer. Bju International 100(6): 1259-1263, 2007

Molecular markers and prostate cancer prognosis. Clinical Prostate Cancer 3(3): 157-164, 2005

Molecular markers and death from prostate cancer. Annals of Internal Medicine 150(9): 595-603, 2009

Relevance of molecular markers in prostate cancer. Annals of Internal Medicine 151(12): 894; Author Reply 894-5, 2010

Molecular markers of prostate cancer outcome. European Journal of Cancer 41(6): 858-887, 2005

Development of molecular markers for prostate cancer local T staging Capsular penetration positive, margin negative disease is associated with matrix metalloproteinases and collagen fragments on the external surface of the prostate gland. Journal of Urology 167(4 Supplement): 224, April, 2002